Genetic and epigenetic collaboration in Parkinson’s disease

Document Type : Review Paper

Authors

Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Abstract

Parkinson's disease (PD) is a common neurodegenerative syndrome directly related to age development. This pathologic condition presents in many types of forms. Some efforts applied to understand PD development include regulation of epigenetic mechanisms, which usually include minor molecular modifications of DNA and histones, which are essential to regulate genetic activity. We have highlighted the problems associated with the development of genetic and epigenetic processes and reviewed several studies. None of these led to more vital conclusions about the autonomous roles of epigenetic pathways. Data from the current standpoint suggested that the SNCA, one of the hallmark genes implicated in PD, is more prevalent than pathways that directly require DNA methylation due to complicated DNA hydroxyl-methylation, global hyper-acetylation and histone deacetylase (HDAC). Without current epigenetic clinical goals to delay PD progression, we hypothesize how PD neurons, with the potential therapeutic objectives, can affect local and global epigenetics via inflammation, oxidative stress, autophagy and DNA repair mechanisms.

Graphical Abstract

Genetic and epigenetic collaboration in Parkinson’s disease

Highlights

  • Parkinson's disease (PD) is a common neurodegenerative syndrome.
  • Reduced activity of dopamine (DA) in Substantia Nigra is linked to PD.
  • Epigenetics and genetics are highly interconnected in PD.
  • 10–15% prevalence of Parkinson's disease has a family-oriented basis.
  • SNCA has a role in the pathogenesis of Parkinson's disease.

Keywords

Main Subjects

References

1. Andersson R, Enroth S, Rada-Iglesias A, Wadelius C, Komorowski J. Nucleosomes are well positioned in exons and carry characteristic histone modifications. Genome Res 2009; 19(10): 1732-1741.
https://doi.org/10.1101/gr.092353.109
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed    PubMed Central
2. Armstrong RA, Lantos PL, Cairns NJ. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?. Neuropathology 2008; 28(4): 351-365.
https://doi.org/10.1111/j.1440-1789.2008.00916.x
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
3. Van Baak TE, Coarfa C, Dugué PA, Fiorito G, Laritsky E, Baker MS, Kessler NJ, Dong J, Duryea JD, Silver MJ, Saffari A. Epigenetic supersimilarity of monozygotic twin pairs. Genome Biol 2018; 19(1): 1-20.
https://doi.org/10.1186/s13059-017-1374-0
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
4. Bae T, Tomasini L, Mariani J, Zhou B, Roychowdhury T, Franjic D, Pletikos M, Pattni R, Chen BJ, Venturini E, Riley-Gillis B. Different mutational rates and mechanisms in human cells at pregastrulation and neurogenesis. Science 2018; 359(6375): 550-555.
https://doi.org/10.1126/science.aan8690
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
5. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21(3): 381-395.
https://doi.org/10.1038/cr.2011.22
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
6. Basu S, Adams L, Guhathakurta S, Kim YS. A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3′ end using CRISPR-Cas9 genome editing technique. Scientific Rep 2017; 7(1): 1-1.
https://doi.org/10.1038/srep45883
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
7. Benayoun BA, Pollina EA, Brunet A. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat Rev Mol Cell Biol 2015; 16(10): 593-610.
https://doi.org/10.1038/nrm4048
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
8. Huse DM, Schulman K, Orsini L, Castelli‐Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Official J Mov Disord Soc 2005; 20(11): 1449-1454.
https://doi.org/10.1002/mds.20609
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
9. De Rijk MD, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54(11): S21-S23. ISSN: 0028-3878
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
10. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157(11): 1015-1022.
https://doi.org/10.1093/aje/kwg068
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
11. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6): 525-535.
https://doi.org/10.1016/S1474-4422(06)70471-9
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
12. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68(5): 384-386.
https://doi.org/10.1212/01.wnl.0000247740.47667.03
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
13. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8(12): 1150-1157.
https://doi.org/10.1016/S1474-4422(09)70238-8
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
14. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997; 388(6645): 839-840.
https://doi.org/10.1038/42166
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
15. Winner B, Kohl Z, Gage FH. Neurodegenerative disease and adult neurogenesis. Eur J Neurosci 2011; 33(6): 1139-1151.
https://doi.org/10.1111/j.1460-9568.2011.07613.x
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
16. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2(7): 492-501.
https://doi.org/10.1038/35081564
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
17. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003; 991: 1-4.
https://doi.org/10.1111/j.1749-6632.2003.tb07458.x
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
18. Lang AE, Lozano AM. Parkinson's disease. New England J Med 1998; 339(16): 1130-1143.
https://doi.org/10.1056/NEJM199810153391607
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
19. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start?. Arch Neurol 2010; 67(7): 798-801.
https://doi.org/10.1001/archneurol.2010.135
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
20. Hawkes CH. The prodromal phase of sporadic Parkinson’s disease: Does it exist and if so how long is it? Mov Disord 2008; 23(13): 1799-1807.
https://doi.org/10.1002/mds.22242
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
21. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 2008; 115(4): 409-415.
https://doi.org/10.1007/s00401-008-0344-8
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
22. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of α-synucleinopathy: relevance in a population-based cohort. Neurology 2008; 70(13): 1042-1048.
https://doi.org/10.1212/01.wnl.0000306697.48738.b6
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
23. Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 2015; 31(3): 140-149.
http://dx.doi.org/10.1016/j.tig.2015.01.004
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
24. Hamza TH, Payami H. The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. J Hum Genet 2010; 55(4): 241-243.
https://doi.org/10.1038/jhg.2010.13
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
25. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Ann Rev Genom Hum Genet 2011; 12: 301-325.
https://doi.org/10.1146/annurev-genom-082410-101440
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
26. Hardy J, Cai H, Cookson MR, Gwinn‐Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006; 60(4): 389-398.
https://doi.org/10.1002/ana.21022
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
27. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010; 31(7): 763-780.
https://doi.org/10.1002/humu.21277
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
28. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364(9440): 1167-1169.
https://doi.org/10.1016/S0140-6736(04)17103-1
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
29. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra AN, Lincoln S, Crawley A. [alpha]-synuclein locus triplication causes Parkinson's disease. Science 2003; 302(5646): 841-842.
https://doi.org/10.1126/science.1090278
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
30. IIbáñez P, Bonnet AM, Débarges B. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364(9440): 1169-1171.
https://doi.org/10.1016/S0140-6736(04)17104-3
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
31. Guardia-Laguarta C, Area-Gomez E, Schon EA, Przedborski S. Novel subcellular localization for α-synuclein: possible functional consequences. Front Neuroanat 2015; 9: 17.
https://doi.org/10.3389/fnana.2015.00017
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
32. Siddiqui A, Chinta SJ, Mallajosyula JK, Rajagopolan S, Hanson I, Rane A, Melov S, Andersen JK. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson’s disease. Free Radic Biol Med 2012; 53(4): 993-1003.
https://doi.org/10.1016/j.freeradbiomed.2012.05.024
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
33. Yu S, Zuo X, Li Y, Zhang C, Zhou M, Zhang YA, Uéda K, Chan P. Inhibition of tyrosine hydroxylase expression in α-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 2004; 367(1): 34-39.
https://doi.org/10.1016/j.neulet.2004.05.118
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
34. Specht CG, Tigaret CM, Rast GF, Thalhammer A, Rudhard Y, Schoepfer R. Subcellular localisation of recombinant α-and γ-synuclein. Mol Cell Neurosci 2005; 28(2): 326-334.
https://doi.org/10.1016/j.mcn.2004.09.017
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
35. Bonifati V. Genetics of Parkinson's disease–state of the art, 2013. Parkinsonism Relat Disord 2014; 20: S23-S28.
https://doi.org/10.1016/S1353-8020(13)70009-9
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
36. Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89(1): 168-175.
https://doi.org/10.1016/j.ajhg.2011.06.008
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
37. Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89(1): 162-167.
https://doi.org/10.1016/j.ajhg.2011.06.001
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
38. Braschi E, Goyon V, Zunino R, Mohanty A, Xu L, McBride HM. Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr Biol 2010; 20(14): 1310-1315.
https://doi.org/10.1016/j.cub.2010.05.066
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
39. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, Marder KS, Honig LS, Clark LN, Small SA, Abeliovich A. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk. Neuron 2013; 77(3): 425-439.
https://doi.org/10.1016/j.neuron.2012.11.033
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
40. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2(1): a008888.
https://doi.org/10.1101/cshperspect.a008888
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
41. Schlossmacher MG, Cullen V, Müthing J. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. New England J Med 2005; 352(7): 728-731.
https://doi.org/10.1056/nejm200502173520719
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
42. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA–induced dyskinesia and histone activation. Biol Psychiatry 2009; 66(6): 603-613.
https://doi.org/10.1016/j.biopsych.2009.04.025
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
43. International Parkinson's Disease Genomics Consortium, Wellcome Trust Case Control Consortium 2 (WTCCC2. A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 2011; 7(6): e1002142.
https://doi.org/10.1016/j.biopsych.2009.04.025
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
44. Kidd SK, Schneider JS. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2011; 194: 189-194.
https://doi.org/10.1016/j.neuroscience.2011.08.010
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
45. Chen PS, Wang CC, Bortner CD, Peng GS, Wu X, Pang H, Lu RB, Gean PW, Chuang DM, Hong JS. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007; 149(1): 203-212.
https://doi.org/10.1016/j.neuroscience.2007.06.053
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
46. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, Hong JS. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Mol Brain Res 2005; 134(1): 162-169.
https://doi.org/10.1016/j.molbrainres.2004.10.021
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
47. Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, Yasuda S, Leeds P, Chuang DM. Valproic acid induces functional heat‐shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009; 111(4): 976-987.
https://doi.org/10.1111/j.1471-4159.2009.06385.x
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
48. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease. Hum  Mol Genet 2008; 17(23): 3767-3775.
https://doi.org/10.1093/hmg/ddn273
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
49. Kidd SK, Schneider JS. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res 2010; 1354: 172-178.
https://doi.org/10.1016/j.brainres.2010.07.041
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
50. Watanabe Y, Maekawa M. Methylation of DNA in cancer. Adv Clin Chem 2010; 52: 145-167.
https://doi.org/10.1016/S0065-2423(10)52006-7
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
51. Chen H, Dzitoyeva S, Manev H. Effect of valproic acid on mitochondrial epigenetics. Eur J Pharmacol 2012; 690(1-3): 51-59.
https://doi.org/10.1016/j.ejphar.2012.06.019
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
52. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Kinyamu H, Lu N, Gao X, Leng Y, Chuang DM. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 2008; 11(8): 1123-1134.
https://doi.org/10.1017/S1461145708009024
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
53. Marinova Z, Leng Y, Leeds P, Chuang DM. Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology 2011; 60(7-8): 1109-1115.
https://doi.org/10.1016/j.neuropharm.2010.09.022
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
54. Leng Y, Marinova Z, Reis-Fernandes MA, Nau H, Chuang DM. Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett 2010; 476(3): 127-132.
https://doi.org/10.1016/j.neulet.2010.04.013
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
55. Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, Freed CR. Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem 2011; 286(17): 14941-14951.
https://doi.org/10.1074/jbc.M110.211029
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
56. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 2001; 47(6): 1102-1104.
https://doi.org/10.1093/clinchem/47.6.1102
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
57. Obeid R, Schadt A, Dillmann U, Kostopoulos P, Fassbender K, Herrmann W. Methylation status and neurodegenerative markers in Parkinson disease. Clin Chem 2009; 55(10): 1852-1860.
https://doi.org/10.1373/clinchem.2009.125021
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
58. Maeda T, Guan JZ, Oyama JI, Higuchi Y, Makino N. Aging-associated alteration of subtelomeric methylation in Parkinson's disease. J Gerontol Series A: Biomed Sci Med Sci 2009; 64(9): 949-955.
https://doi.org/10.1093/gerona/glp070
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
59. Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsońs disease. J Biotechnol 2011; 152(3): 96-101.
https://doi.org/10.1016/j.jbiotec.2011.01.023
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
60. Miñones-Moyano E, Porta S, Escaramís G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Martí E. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 2011; 20(15): 3067-3078.
https://doi.org/10.1093/hmg/ddr210
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
61. Kopin IJ. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Adv Neurol 1987; 45: 137-144. ISSN: 00913952
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
62. Fukuda T. Neurotoxicity of MPTP. Neuropathology 2001; 21(4): 323-332.
https://doi.org/10.1046/j.1440-1789.2001.00402.x
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
63. Van Maele-Fabry G, Hoet P, Vilain F, Lison D. Occupational exposure to pesticides and Parkinson's disease: a systematic review and meta-analysis of cohort studies. Environ Int 2012; 46: 30-43.
https://doi.org/10.1016/j.envint.2012.05.004
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
64. Zaheer F, Slevin JT. Trichloroethylene and Parkinson disease. Neurol Clin 2011; 29(3): 657-665.
https://doi.org/10.1016/j.ncl.2011.05.001
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
65. Franco R, Li S, Rodriguez-Rocha H, Burns M, Panayiotidis MI. Molecular mechanisms of pesticide-induced neurotoxicity: Relevance to Parkinson's disease. Chem Biol Interact 2010; 188(2): 289-300.
https://doi.org/10.1016/j.cbi.2010.06.003
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
66. Kanthasamy A, Jin H, Anantharam V, Sondarva G, Rangasamy V, Rana A, Kanthasamy A. Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology 2012; 33(4): 833-837.
https://doi.org/10.1016/j.neuro.2012.01.011
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
67. Song C, Kanthasamy A, Anantharam V, Sun F, Kanthasamy AG. Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol 2010; 77(4): 621-632.
https://doi.org/10.1124/mol.109.062174
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
68. Song C, Kanthasamy A, Jin H, Anantharam V, Kanthasamy AG. Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. Neurotoxicology 2011; 32(5): 586-595.
https://doi.org/10.1016/j.neuro.2011.05.018
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
69. Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG. Striatal histone modifications in models of levodopa‐induced dyskinesia. J Neurochem 2008; 106(1): 486-494.
https://doi.org/10.1111/j.1471-4159.2008.05417.x
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
70. Thomas B, Mandir AS, West N, Liu Y, Andrabi SA, Stirling W, Dawson VL, Dawson TM, Lee MK. Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation. PloS One 2011; 6(1): e16706.
https://doi.org/10.1371/journal.pone.0016706
CrossRef    Google Scholar    full-text PDF    Mendeley    PubMed
71. Jones PA, Archer TK, Baylin SB, Beck S, Berger S, Bernstein BE, Carpten JD, Clark SJ, Costello JF, Doerge RW, Esteller M. Moving AHEAD with an international human epigenome project. Nature 2008; 454(7205): 711.
https://doi.org/10.1038/454711a
CrossRef    Google Scholar    full-text PDF    Mendeley  
Central Asian Journal of Medical and Pharmaceutical Sciences Innovation
Volume 1, Issue 4
July and August 2021
Pages 165-175

Files

Share

How to cite

Statistics